CD8+ S100B+ T cells

Overview

CD8+ S100B+ T cells are a phenotypically distinct subset of CD8+ cytotoxic T lymphocytes identified by co-expression of the S100B protein marker alongside the canonical CD8 surface antigen and T cell receptor complex. These cells represent a specialized population within the broader CD8+ T cell compartment with demonstrable relevance to immune-mediated inflammatory diseases, particularly psoriasis. Recent Mendelian randomization studies have identified CEBPD (CCAAT/enhancer binding protein delta) transcription factor expression specifically in CD8+ S100B+ T cells as a protective genetic factor against psoriasis development, indicating that this subset possesses distinct transcriptional programming that modulates disease susceptibility and immune homeostasis.

Like other CD8+ T cells, CD8+ S100B+ T cells are presumed to function as cytotoxic effector lymphocytes capable of antigen recognition and killing of infected or abnormal target cells through perforin and granzyme-mediated mechanisms. The precise functional and developmental significance of S100B co-expression—whether associated with tissue residency, developmental maturation state, metabolic programming, or specialized immune functions—remains incompletely understood. The identification of this subset illustrates functional heterogeneity within the CD8+ T cell pool and exemplifies how high-resolution immunophenotyping integrated with genetic approaches can reveal cell-type-specific disease mechanisms and potential therapeutic targets in immune-mediated pathology.

Recent Publications Summary

Recent studies have implicated CD8+ S100B+ T cells in psoriasis biology through multi-omics and causal inference analyses. In one integrative study, CEBPD was identified as having cell-type-specific causal effects in CD8+ S100B+ T cells, with the authors linking this regulatory signal to protective and risk phenotypes in psoriasis 41991682Apr. The work combined transcriptomic datasets, weighted gene co-expression network analysis, differential expression analysis, protein-protein interaction mapping, machine learning, and Mendelian randomization to prioritize disease-relevant genes and infer their functional contribution 41991682Apr.

Across the broader recent literature on CD8+ T-cell biology, several studies focused on mechanisms that may be relevant to CD8+ S100B+ T-cell states, particularly exhaustion, memory formation, and antitumor effector function. Trans-vaccenic acid delivered by remotely activated lipid nanoparticle reduced CD8+ T-cell exhaustion through activation of the cAMP-PKA-CREB axis and improved PD-L1 blockade responses in tumor models 42261893Jun. GSK-3 was reported to regulate progenitor and memory CD8+ T-cell differentiation, with reduced GSK-3 favoring stem-like and memory-phenotype programs and enhancing antiviral and antitumor immunity 42156357May. Similarly, CD28-driven ex vivo stimulation using CD3-independent artificial antigen-presenting cells generated CD8+ T cells with stem cell-like memory features, including high TCF1 expression, metabolic fitness, and resistance to exhaustion 42012954Apr.

Other studies examined how the tumor microenvironment and immunotherapy shape CD8+ T-cell function. Intratumoral virus-like particles containing a TLR9 agonist increased tumor-specific CD8+ T-cell infiltration and antitumor activity, and the addition of anti-PD-1 produced more sustained tumor control 41960903Apr. In metastatic NSCLC, spatial single-cell proteotyping found that CD8+ T cells were the intratumoral lymphocyte subset most closely associated with immune checkpoint inhibitor efficacy, with direct physical interactions between CD8+ tumor-infiltrating lymphocytes and cancer cells appearing important for response 41805727Mar. In ovarian carcinoma, NKG2A blockade improved NK cell cytotoxicity and promoted CD8+ T-cell responses, highlighting functional crosstalk between these populations in antitumor immunity 41998001Apr.

Additional work described strategies that selectively modulate effector CD8+ T-cell persistence and function. LTβR blockade reduced accumulation of IFN-γ-producing effector CD8+ T cells and separated anti-CD137 efficacy from hepatotoxicity, while preserving tumor-specific CD8+ T-cell responses 42018612Apr. Fractalkine-conjugated mRNA lipid nanoparticle enabled highly efficient in vivo delivery to CX3CR1+ cytotoxic effector CD8 T cells in mice and rhesus macaques, demonstrating a platform for transient reprogramming of these cells 42102231May. In glioblastoma, enhancing antigen cross-presentation by M2-like tumor-associated macrophages was proposed as a way to boost CD8+ T-cell activation and improve immunotherapy 41370882Dec.

What Changes, What Holds

1. CEBPD now looks like a cell-type-specific protective signal in psoriasis rather than a generic association
REINFORCES Multi-omics plus causal inference sharpen the baseline claim that CD8+ S100B+ T cells carry disease-relevant transcriptional programming, and they strengthen the idea that CEBPD within this subset is linked to protection against psoriasis 41991682Apr. The main change is not a new role for the cells, but greater confidence that the signal is specific to this subset and biologically meaningful rather than a broad CD8+ T-cell effect.

2. Recent CD8+ T-cell work extends the likely functional frame of CD8+ S100B+ states toward memory, exhaustion, and effector fitness
NEW DIRECTION These studies do not overturn the baseline cytotoxic-lymphocyte model, but they add plausible state-level biology that the Overview does not yet assign to CD8+ S100B+ T cells: stem-like memory programs, resistance to exhaustion, and metabolic fitness 42156357May42012954Apr. Because the baseline is silent on these features, the work suggests candidate functional states rather than a revised identity for the subset.

3. CD8+ T-cell performance in tumors is emerging as a context where this subset may matter, but not as a distinct established role
NEW DIRECTION The new tumor and immunotherapy studies broaden the setting in which CD8+ T-cell function is being linked to disease control, yet they do not specifically establish a new role for CD8+ S100B+ T cells beyond the baseline cytotoxic framework 41960903Apr41805727Mar. What changes is the surrounding biology: these cells may be worth tracking in checkpoint response and intratumoral activity, but that remains inferential rather than demonstrated for this subset.

4. Effector CD8+ T-cell persistence can be selectively tuned, which may eventually be relevant to CD8+ S100B+ T-cell manipulation
METHOD The delivery and blockade studies mainly change how CD8+ T cells are modulated and measured, not what is known about CD8+ S100B+ T cells themselves 42018612Apr42102231May. They provide technical and translational tools for transient reprogramming or selective preservation of effector populations, but they do not yet assign a new biological function to the S100B+ subset. The glioblastoma macrophage result is similarly upstream of the subset-specific baseline.

Overview update candidates: CEBPD as a cell-type-specific protective factor in CD8+ S100B+ T cells; possible links of the broader CD8+ T-cell state space to memory; exhaustion; and effector fitness.